MOTRIN IB MENSTRUAL PAIN TABLET
Pajjiż: Kanada
Lingwa: Ingliż
Sors: Health Canada
Karatteristiċi tal-prodott
(SPC)
26-09-2012
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
IBUPROFEN
Disponibbli minn:
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
Kodiċi ATC:
M01AE01
INN (Isem Internazzjonali):
IBUPROFEN
Dożaġġ:
200MG
Għamla farmaċewtika:
TABLET
Kompożizzjoni:
IBUPROFEN 200MG
Rotta amministrattiva:
ORAL
Unitajiet fil-pakkett:
100
Tip ta 'preskrizzjoni:
OTC
Żona terapewtika:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Sommarju tal-prodott:
Active ingredient group (AIG) number: 0108883004; AHFS:
L-istatus ta 'awtorizzazzjoni:
CANCELLED PRE MARKET
Data ta 'l-awtorizzazzjoni:
2016-01-22
Karatteristiċi tal-prodott
PRODUCT MONOGRAPH
MOTRIN
®
IB Menstrual Pain
Ibuprofen Tablets USP, 200 mg
Super Strength MOTRIN
®
IB Menstrual Pain
Ibuprofen Tablets USP, 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
McNeil Consumer Healthcare
Division of Johnson & Johnson Inc.
88 McNabb Street
Markham, Canada
L3R 5L2
www.motrin.ca
Date of Revision:
September 20, 2012
CONTROL NUMBER: 156423
_ _
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND STABILITY
..........................................................................................18
SPECIAL HANDLING INSTRUCTIONS
.......................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................20
PHARMACEUTICAL INFORMATION
..................................................................
Aqra d-dokument sħiħ
